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HIV-1 viral load measurements over the 
first year since HIV-1 diagnosis in the 
RV144 (left) and Step (right) trials. The 
mean viral load and associated 95% 
confidence interval at each time is 
shown for subjects with homogeneous 
vs. heterogeneous founding viral 
populations at the time of diagnosis. 
Means are estimated using models that 
adjust for baseline subject 
characteristics and assume that the 
effects of heterogeneity are constant 
over time. 
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The term viral load denotes the number of HIV particles, quantified by detection of the viral RNA, in a 
milliliter of blood. This value increases soon after the infection then drops and stabilizes at a value 
termed viral set point. A lower set point correlates with a slower progression of the infection. Viral 
load set point, while being fairly stable for a single individual, varies across individuals, highlighting 
the importance of host characteristics in establishing it. This variability may be accounted for by 
host-virus interactions as well as by differences in characteristics of the viral infection, such as an 
infection with multiple HIV variants. While this is a rare event as compared to the infection with a 
single variant, it accounts for 20-35% new infections. 
To evaluate whether infection with multiple HIV founders is associated with a higher viral load, Dr. 
Holly Janes from the Vaccine and Infectious Disease Division at Fred Hutch and collaborators from 
other institutions in US and Thailand analyzed two sets of data, obtained from breakthrough 
infections in RV144 and Step vaccine efficacy trials. RV144, also known as the Thai trial, tested a 
vaccine designed to induce antibodies against the envelope (Env) protein of HIV, and recruited 
volunteers in Thailand. The vaccine evaluated in the Step study induces T cell responses and was 
tested on subjects recruited at several study sites located in the Americas. Two different measures 
of the diversity of the founder virus population at the time of HIV diagnosis were used, a categorical 
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measure (homogeneous vs. heterogeneous virus population) and a continuous measure of env gene 
diversity.  
In the samples from the RV144 trial, a higher average viral load was observed in the subjects with 
heterogeneous viral infections as compared to those with homogeneous infections at the time of 
detection of HIV infection as well averaged over times within 1- and 2-years of infection diagnosis. 
Accordingly, a lower average CD4+ T cell count was observed in subjects with heterogeneous 
infections. Interestingly, although the associations with viral load at later time points were similar for 
the Step study, heterogeneous infections were not found to be correlated with a higher viral load at 
the time of infection and the average CD4+ T cell count was comparable in subjects with 
heterogeneous and homogeneous founding virus populations. The difference between the two 
studies was not explained by the differences between the vaccines.  
The study identified infection with multiple HIV founders as a factor potentially involved in the 
establishment of the viral set point. "This research suggests that a prophylactic intervention that 
reduced the number of founding viruses in a person who becomes HIV infected could have clinical 
benefit, and motivates measuring the number of founding viruses in future efficacy trials of these 
interventions" said Dr. Janes commenting on the results. Given the relevance that the viral set point 
has on the progression of the disease, the finding is important not only to better understand the 
progression of HIV infection, but it might have a clinical relevance. 
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